TRACT (TRAining in Cancer mechanisms & Therapeutics) - Marie Skłodowska-Curie PhD Fellowships
31st December 2016 is the deadline for applying to the call for 11 PhD positions offered within the frame of TRACT
TRACT is an international, inter-sectoral, multi-disciplinary project providing 11 Marie Skłodowska-Curie PhD Fellowships to early stage researchers (ESRs) with the potential to become the leaders of tomorrow in cancer research.
Applicants should possess a high standard of written and spoken English. Prospective PhD candidates should hold at least a 2:1 BSc or alternatively an MSc degree, or equivalent, in biochemistry, molecular biology, immunology, medicinal chemistry, synthetic organic chemistry or related disciplines. Graduates in dental science with a special interest in oral medicine are also encouraged to apply.
Eligible candidates must not have resided in the country where the research training activities take place for more than 12 months in the 3 years immediately prior to the recruitment date (and not have carried out their main activity - work, studies, etc. - in that country).
- ESR1 - Inflammatory response elements, and glycan and proteome profiles as salivary biomarkers for the early diagnosis of OSCC,
- ESR2 - Identification of novel molecular biomarkers predictive of benefit to neo-adjuvant chemotherapy in OAC,
- ESR3 - Modulation of salivary inflammatory markers and proteomic analysis in patients undergoing radiotherapy for OSCC & cancer of the head and neck,
- ESR4 - A pathways-based approach to identify determinants of drug resistance in OAC,
- ESR5 - Inflammatory caspases as biomarkers for OAC? Determining the role of inflammatory caspases in OAC development and resistance,
- ESR7 - HAMLET derivatives as a pre-operative therapy in oesophageal cancer,
- ESR9 - Pre-clinical evaluation of targeting autophagy for the treatment of OSCC,
- ESR10 - Metabolic profiles in normal, dysplastic and cancerous oral cells,
- ESR11 - Mitochondrial function linked to metabolic differences in normal, dysplastic and cancerous oral cells.
► Contact info: